CStone Pharmaceuticals (SEHK: 2616)
Health Care · Biotechnology · CN
HK$5.09
-9.99% today · -28.9% 1Y
CStone Pharmaceuticals (SEHK: 2616) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.03B and employs 102 people.
Over the last twelve months the share price has lost 28.9%, trading between 4.01 and 10.41.
Tweenvest scores CStone Pharmaceuticals across four factors: quality 38/100, value 70/100, growth 0/100. Its strongest factor is value.
2616 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.03B
- Revenue (TTM)
- $62.60M
- P/E
- —
- EPS
- -0.28
- Dividend yield
- —
- Beta (5Y)
- 0.22
- 52-week high
- HK$10.41
- 52-week low
- HK$4.01
- Avg volume (3M)
- —
- Shares outstanding
- 1.59B
- Employees
- 102
- Next earnings
- —
About CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
- ISIN
- KYG2588M1006
- Founded
- 2015
- Listed since
- Feb 26, 2019
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GC Biopharma Corp.KOSE: A006280 | $1.10B | ₩129,400.00 | +2.86% |
| Chengdu Kanghua Biological Products Co., Ltd.SZSE: 300841 | $1.07B | CN¥55.26 | -1.95% |
| Beijing Strong Biotechnologies,Inc.SZSE: 300406 | $1.06B | CN¥12.14 | +1.68% |
| MannKind CorporationNasdaqGM: MNKD | $1.06B | $3.13 | -4.86% |
| MeiraGTx Holdings plcNasdaqGS: MGTX | $1.03B | $10.38 | -2.95% |
| Immatics N.V.NasdaqCM: IMTX | $1.02B | $7.20 | -3.10% |
| Kolon TissueGene, Inc.KOSDAQ: A950160 | $1.01B | ₩16,030.00 | -0.62% |
| Aktis Oncology, Inc.NasdaqGS: AKTS | $1.01B | $17.54 | -3.36% |
Figures last refreshed Oct 11, 2026.